Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

JetBlue Airways Corp JBLU

JetBlue Airways Corporation provides air transportation services across the United States, the Caribbean, Latin America, Canada, and Europe. The Company's segments include Domestic & Canada, Caribbean & Latin America and Atlantic. It operates five types of aircraft: Airbus A220, Airbus A320, Airbus A321, Airbus A321neo, and Embraer E190. It offers an inflight entertainment system onboard on its aircraft, which includes free live TV on select routes and premium movie channel offerings from JetBlue Features. Its entire fleet is equipped with Fly-Fi, a broadband product that allows gate-to-gate Wi-Fi at every seat. Customers also have access to the Fly-Fi Hub, a content portal where customers can access a wide range of additional content from their own personal devices. It also sells vacation packages through its wholly owned subsidiary, JetBlue Travel Products, LLC (JBTP), which offers one-stop, value-priced vacation services for self-directed packaged travel planning.


NDAQ:JBLU - Post by User

Post by KarenCaron Feb 05, 2022 2:18am
248 Views
Post# 34400485

FSD Pharma Inc: Lucid MS Video

FSD Pharma Inc: Lucid MS VideoFSD Pharma is pleased to share pre-clinical data demonstrating the effectiveness of its lead drug candidate, Lucid-MS, in treating Multiple Sclerosis. The unique potential therapeutic value of Lucid-MS is an industry-first and we want to share the visual evidence of functional recovery of pre-clinical subjects in this video!
<< Previous
Bullboard Posts
Next >>